Post-marketing surveillance: why medical device safety doesn’t end with certification

10.12.2025

Quality management // № 12, December 2025

Market leaders have long viewed post-marketing surveillance not as a costly obligation, but as an investment in their own future. There are examples in the history of medical technology when critical flaws were later discovered in the latest developments that received certification. Mass product recalls, lawsuits, destroyed consumer trust – all this cost companies much more than the development of a timely and transparent monitoring system.

The text of the article is available only in Ukrainian

Other news

25.09.2024

33 International Medical Exhibition PUBLIC HEALTH 2024, 2-4 October, IEC

Read more
24.06.2020

Comparison of sterilization methods

Read more
28.02.2019

Legalization of import products for the Ukrainian market of medical products

Read more